News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Granules India receives 1 observation from USFDA for Chantilly facility
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
There are 38.4 million people with diabetes in the United States
Approval is based on positive data from the Phase 3 ECHELON-3 trial
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
